Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Oh, the Places Grads Go
Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium
Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”
Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.